Synta Pharmaceuticals Corp. Stock Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 75.76M 103M | Sales 2025 * | 361M 491M | Capitalization | 4.5B 6.11B |
---|---|---|---|---|---|
Net income 2024 * | -583M -793M | Net income 2025 * | -403M -548M | EV / Sales 2024 * | 50.2 x |
Net cash position 2024 * | 694M 943M | Net cash position 2025 * | 292M 397M | EV / Sales 2025 * | 11.6 x |
P/E ratio 2024 * |
-7.47
x | P/E ratio 2025 * |
-11.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.94% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |